What is Ovarian Cancer?
Ovarian cancer is a type of cancer that affects women’s ovaries, the small organs that produce eggs for reproduction.
This disease is hard to detect early because it often doesn’t show noticeable symptoms until it has spread within the pelvis and belly.
At this advanced stage, ovarian cancer is more challenging to treat and can be fatal.
High Grade Serous Carcinoma (HGSC) is a subtype of ovarian cancer. It is particularly aggressive and presents the worst survival rates among ovarian cancer patients.
Currently, less than half of the women diagnosed with HGSC live longer than five years.
Challenges in Treating Ovarian Cancer
A major hurdle in the fight against ovarian cancer is its genetic complexity. Like a chameleon, it constantly changes and adapts, making it hard to study and even harder to treat.
This is particularly true for HGSC. Because each tumor can be quite different genetically, it’s difficult to find a one-size-fits-all treatment approach.
New Breakthroughs in Ovarian Cancer Research
However, recent research from scientists at various Finnish and Danish universities has shed new light on HGSC.
They’ve been able to sort HGSC tumors into three different groups. Each group has unique characteristics, such as how they grow and how they respond to treatment.
This study, which was published in the scientific journal “Cancer Cell,” is a big step forward. It means that doctors may soon be able to personalize treatment based on the specific type of HGSC a patient has.
The Three Types of HGSC Tumors
The scientists studied tumor samples from 148 HGSC patients. They found that the tumors fell into three categories, or “evolutionary states,” which they called “evolving,” “maintaining,” and “adaptive.”
“Evolving” tumors keep changing, and the cells within the tumor are all genetically different. “Maintaining” tumors, on the other hand, are more uniform.
The cells within the tumor are genetically identical or “clonal.” Finally, “adaptive” tumors change over time in response to treatment or the body’s immune response.
The researchers also found that each of these three types of tumors has a unique “signaling pathway.”
A signaling pathway is a group of molecules in a cell that work together to control one or more cell functions, like cell division or cell death.
By understanding these signaling pathways, doctors can develop new treatments targeted directly at these specific tumor types.
Improving Treatment for HGSC Patients
One of the signaling pathways the researchers found is particularly important for “adaptive” tumors. This pathway, called PI3K/AKT, controls several cellular processes, including cell growth and survival.
There are already drugs available that can target this pathway, but until now, doctors didn’t know which patients were most likely to benefit from them.
The findings from this study mean doctors can now identify patients with “adaptive” tumors who are likely to respond well to these drugs. This could lead to more effective, personalized treatment plans for these patients.
What’s Next for Ovarian Cancer Research?
This research is a major breakthrough, but there’s still a lot of work to be done. The researchers are now looking for the best way to classify patients into these three groups based on their tumors.
This research is a shining example of the world-class work being done in Finland. Despite its small population, the country is making big strides in ovarian cancer research.
The hope is that these findings will accelerate the entire field of ovarian cancer research, making it easier to develop new, targeted therapies.
With more effective treatments, we can improve survival rates for women diagnosed with this aggressive form of cancer.
If you care about cancer, please read studies that a low-carb diet could increase overall cancer risk, and vitamin D supplements could strongly reduce cancer death.
For more information about health, please see recent studies about how drinking milk affects the risks of heart disease and cancer and results showing dairy foods may increase men’s risk of prostate cancer.
The study was published in Cancer Cell.
Copyright © 2023 Knowridge Science Report. All rights reserved.